CClinicalTrials.gg
CompletedNCT02741713Updated Aug 27, 2018Results posted

Analgesic Benefit of PECS Blocks for Biceps Tenodesis Shoulder Surgery

A Phase 3 interventional study of PECS "Pectoralis" 1 and 2 Blocks and Interscalene Block in Biceps Tendonitis, sponsored by Wake Forest University Health Sciences. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-27.

Sponsored by Wake Forest University Health Sciences · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The standard practice for arthroscopic shoulder surgery at our institution is a general anesthetic with a long-acting interscalene block for post-operative pain control, which can reduce the amount of opiates needed after surgery. The interscalene block is effective in providing analgesia to the majority of the shoulder joint and has been shown to reduce post-operative pain scores after arthroscopic shoulder surgeries. However, there is a subset of arthroscopic shoulder surgery patients who have pain in the axilla even in the setting of a functioning interscalene brachial plexus nerve block. One of our surgeons has reported a high incidence of axillary pain in patients who undergo a sub-pectoral biceps tenodesis as part of their arthroscopic procedure. A newly described nerve block approach to the nerves that supply sensation to the axillary region called the PECS "Pectoralis" 1 \& 2 block may provide additional analgesia to these patients.

The purpose of this prospective, randomized, observer and patient blinded, single-center, sham block trial is to determine if the addition of PECS blocks to an interscalene block will reduce the severity of axillary pain following arthroscopic shoulder surgery that involves a sub-pectoral biceps tenodesis. Secondarily, the study will assess the duration of PECS 1 \& 2 and whether the block reduces post-operative opioid usage. We hypothesize that the addition of the PECS 1 \& 2 block will reduce the severity of axillary pain at 6hrs and reduce postoperative narcotic usage for the first 24 hours.

Read the detailed description

Subjects that meet the inclusion criteria will be assigned a group by using a random numbers generator. All subjects will receive the standard practice at our institution of an interscalene brachial plexus block along with a general anesthetic. The intervention arm will get an additional local anesthetic block targeting nerves that we presume cover the axillary region (PECS "Pectoralis" 1 \& 2). These nerves in the upper chest are the lateral branches of the 2nd to 5th intercostal nerves, which includes the intercostobrachial nerve. The anesthesiologist placing the nerve blocks will be un-blinded to perform the procedures. Both the surgeon and the Acute Pain Service anesthesiologist will be blinded as to whether or not the intervention was provided to any given subject. The Acute Pain Service team will remain blinded and collect the data outcomes.

Initially, pilot data was collected in a total of ten patients with five patients randomized to each arm. Primary endpoint was NRS "Numerical Rating Scale" of 0-10 at 6hrs after block placement. Our pilot data indicate that the mean NRS is about 5 for the control group, with a standard deviation of 1.4. Using a two-sided two-sample t test (an alpha of 0.05 and power of 0.95), we conservatively estimate that 14 subjects per arm will be needed to detect a clinically meaningful difference of 2 in NRS between the arms. We decided to plan enrollment of 20 subjects per arm for potential loss during this randomized, double-blinded, single-center, sham block trial.

  • Potential subjects undergoing arthroscopy will have their electronic medical record reviewed by the study team to look for exclusion criteria. If the subject is excluded, then they will be added to the Screening Log with date and reason for their exclusion. If all inclusion criteria are met, then the subject will be approached in the Regional Anesthesia area for their consent. A copy of the consent will be given to the study subject. The other informed consent document will be maintained by the study team in the research files.
  • Patients will be asked to provide baseline pain scores both, at rest and with movement, on a scale of 0-10 (0 being no pain and 10 being the worst pain). Preoperative opioid use including drug(s), dosage and frequency will be recorded. Randomization of patients will then occur through the use of sequentially numbered envelopes with only those directly involved in the care of the patient during block placement being aware of which arm of the study the patient has been randomized. Those members of the study team who will be collecting post-operative data will be blinded to the randomization.

Standard American Society of Anesthesiology monitors and oxygen will be applied. Unless there is a contraindication, each patient will receive 650mg "milligrams" of oral acetaminophen. To standardize the effect on postoperative pain, ketamine will not be given as a preoperative sedation medication or intraoperative medication. No long acting opioids will be given in the operating room or post-anesthesia care unit. Intraoperative fentanyl will be limited to 5 micrograms per kg "kilogram". Intraoperative dexamethasone will not be given for post-operative nausea/vomiting prophylaxis.

Subjects will be sedated as per usual practice and will also be blinded to their randomization. All peripheral nerve blocks will be performed by a resident or fellow under supervision by an attending anesthesiologist. The attending anesthesiologist may perform the procedures alone. All volumes and concentrations of nerve block mixtures administered will be identical to assist in the blinding process.

All 40 subjects will receive an ultrasound guided interscalene nerve block using 20mL "milliliters" of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. The intervention arm, consisting of 20 patients, will additionally receive the following: 10mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine at the PECS1 location and 20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine at the PECS2 location as described by Blanco, et al.3,4 All procedures will be performed under a sterile technique including the use of chlorhexidine prep of the skin, sterile gloves, sterile ultrasound probe covers with sterile ultrasound gel, a cap and a mask. For the interscalene block, a 21 gauge 90mm "millimeter" stimulating block needle will be directed, under real-time ultrasound guidance, into the interscalene muscle space at the level of the 5th and 6th cervical nerve roots. Twenty mL of the above local anesthetic mixture will be dosed incrementally, aspirating every 5 mL, to surround the upper trunk of the brachial plexus. For the PECS 1 \& 2 block, a 21 gauge 90mm stimulating block needle will be placed under real-time ultrasound guidance at approximately the level of the 4th and 5th ribs near the mid-axillary line. The needle will be advanced into a tissue plane between the serratus anterior muscle and the pectoralis minor muscle. Twenty mL of the same local anesthetic mixture will be dosed incrementally, every 5 mL, to spread within this PEC2 space. The needle will be withdrawn, following the first injection, to a tissue plane between the pectoralis minor and pectoralis major muscles. Ten mL of the same local anesthetic mixture will be dosed incrementally, every 5 mL, to spread within this PEC1 space.

Fifteen and 30 minutes (if no change at 15min) following block placement, success will be assessed by absence/decrease of pin-prick sensation to a 25 gauge Whitacre needle in the following manner:

Cutaneous sensation will be tested over the deltoid region to assess for successful interscalene block.

Cutaneous sensation will be tested over the lateral aspect of the pectoralis muscles at the level of the nipple.

Scoring of sensation will be the following: 0= full sensation, 1= partial sensation, 2= no sensation (complete block) Following block placements, the subjects will be transported to the OR and general anesthesia will be induced. Following intubation, surgical procedure, emergence and extubation, the subject will be transported to the recovery room. In the recovery room or via phone post-discharge, at the 6 hour mark post-block placement, we will ask the subject if they are having any axillary pain. The severity of pain will be determined using the Numerical Rating Scale of 0-10. Zero is no pain and 10 is the most pain possible. Total opiate and benzodiazepine doses will be charted for the preoperative, intraoperative and PACU time frames.

02

Conditions studied

  • Biceps Tendonitis

Browse trials for

03

In context

Tendinopathy

413 studies on the registry are indexed under Tendinopathy; 64 are open to participants now.

This study's enrollment of 40 is below the median of 50 across 339 interventional studies indexed under Tendinopathy.

Browse Tendinopathy studies →

Lead sponsor

Wake Forest University Health Sciences is the lead sponsor of 1,320 studies on the registry; 199 are open to participants now.

Of its 323 completed or terminated interventional studies of FDA-regulated products, 243 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Adults, between 18 and 80 years of age
  • Ability to take pills
  • Agreement to a regional with general anesthesia technique

Exclusion criteria

Exclusion Criteria:

  • Allergy to amide local anesthetics
  • Presence of a progressive neurological deficit
  • pre-existing coagulopathy
  • Current infection
  • Significant pulmonary disease contraindicating phrenic nerve blockade
  • Chronic use of an opioid analgesic (>3 months of a combined total of more than 40mg oxycodone equivalents a day)
  • Inability to obtain ultrasound images of anatomy due to obesity.
  • Pregnancy
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Sham comparator
    Interscalene Block plus Sham Block

    Twenty subjects will receive an ultrasound guided interscalene nerve block using the Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. A Sham Block of in area of PECS "Pectoralis" block will be done to allow for assessment of the intervention. Using the Solution for Injection in Sham Block.

    Procedure: Interscalene Block · Procedure: Sham Block · Drug: Solution for Injection in Interscalene Block · Drug: Solution for Injection in Sham Block

  • Active comparator
    Interscalene plus PECS Blocks

    Twenty patients will receive an ultrasound guided interscalene nerve block Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. For the Intervention, these subjects will also a PECS "Pectoralis" 1 and 2 Blocks using the Solution for Injection PECS Blocks, dosed at the PECS1 location and PECS2 location as described by Blanco, et al.

    Procedure: PECS "Pectoralis" 1 and 2 Blocks · Procedure: Interscalene Block · Drug: Solution for Injection in Interscalene Block · Drug: Solution for Injection PECS Blocks

Interventions

  • ProcedurePECS "Pectoralis" 1 and 2 Blocks

    An interscalene and a PECS "Pectoralis" 1 and 2 block will be performed on the subjects.

  • ProcedureInterscalene Block

    An interscalene block will be performed on the subjects.

  • ProcedureSham Block
  • DrugSolution for Injection in Interscalene Block

    20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine

    Also known as: bupivacaine, epinephrine, clonidine

  • DrugSolution for Injection in Sham Block

    Lidocaine 1%

    Also known as: Lidocaine

  • DrugSolution for Injection PECS Blocks

    10mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS1 location and 20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS2 location

    Also known as: bupivacaine, epinephrine, clonidine

06

What researchers measure

Primary outcomes

  1. Post-operative Axillary Pain

    Post-operative ambulatory surgery subjects will be asked 6 hours after block placement about the presence of axillary pain at rest. Numerical Rating Scale scores (0-10) will be recorded with 0= no pain, 10=most pain possible. Higher scores denotes worse outcome.

    Time frame: 6 hours post-block.

Secondary outcomes

  1. Numerical Rating Scale Pain Scores (0-10) at Rest

    Subjects were asked about their overall shoulder pain during the followup phone call at 24hrs post-block. Numerical Rating Scale scores (0-10) will be recorded with 0= no pain, 10=most pain possible. Higher scores denotes worse outcome.

    Time frame: Assessed 24hrs post-block on a scale from 0-10.

  2. Percentage of Participants With Episodes of Nausea or Vomiting

    Any episodes during the first 24 hours will be recorded as a yes.

    Time frame: Assessed 24hrs post-block (yes/no)

  3. Total Opioid Usage

    Recorded in oxycodone equivalents in the first 24 hours post-discharge from the PACU.

    Time frame: Assessed 24hrs post-block in mg

  4. Time From Block Placement to Onset of Axillary Pain

    Time self-reported by patients in the Interscalene Plus PECS Blocks group during data collection phone call at 24 hours post-block.

    Time frame: Assessed 24hrs post-block in hours

07

Results

Posted Aug 27, 2018
Limitations and caveats
Only 8 patients in the PECS group reported the onset of axillary pain at home, so that data set is very limited.

Participant flow

Participant flow — Overall Study
MilestoneInterscalene Block Plus Sham BlockInterscalene Plus PECS Blocks
Started2020
Completed1819
Not completed21
Withdrew: Surgery type changed intra-operatively21

Outcome measures

PrimaryPost-operative Axillary Pain

Post-operative ambulatory surgery subjects will be asked 6 hours after block placement about the presence of axillary pain at rest. Numerical Rating Scale scores (0-10) will be recorded with 0= no pain, 10=most pain possible. Higher scores denotes worse outcome.

Time frame:
6 hours post-block.
Reported as:
Median · units on a scale
Post-operative Axillary Pain
units on a scaleInterscalene Block Plus Sham BlockInterscalene Plus PECS Blocks
Post-operative Axillary Pain3 (0 to 5.25)0 (0 to 1.5)
SecondaryNumerical Rating Scale Pain Scores (0-10) at Rest

Subjects were asked about their overall shoulder pain during the followup phone call at 24hrs post-block. Numerical Rating Scale scores (0-10) will be recorded with 0= no pain, 10=most pain possible. Higher scores denotes worse outcome.

Time frame:
Assessed 24hrs post-block on a scale from 0-10.
Reported as:
Median · units on a scale
Numerical Rating Scale Pain Scores (0-10) at Rest
units on a scaleInterscalene Block Plus Sham BlockInterscalene Plus PECS Blocks
Numerical Rating Scale Pain Scores (0-10) at Rest6 (5 to 7)6 (4 to 7)
SecondaryPercentage of Participants With Episodes of Nausea or Vomiting

Any episodes during the first 24 hours will be recorded as a yes.

Time frame:
Assessed 24hrs post-block (yes/no)
Reported as:
Number · percentage of participants
Percentage of Participants With Episodes of Nausea or Vomiting
percentage of participantsInterscalene Block Plus Sham BlockInterscalene Plus PECS Blocks
Percentage of Participants With Episodes of Nausea or Vomiting3937
SecondaryTotal Opioid Usage

Recorded in oxycodone equivalents in the first 24 hours post-discharge from the PACU.

Time frame:
Assessed 24hrs post-block in mg
Reported as:
Mean · mg
Total Opioid Usage
mgInterscalene Block Plus Sham BlockInterscalene Plus PECS Blocks
Total Opioid Usage31.6 (24.1 to 39.0)26.9 (21.8 to 32.0)
SecondaryTime From Block Placement to Onset of Axillary Pain

Time self-reported by patients in the Interscalene Plus PECS Blocks group during data collection phone call at 24 hours post-block.

Time frame:
Assessed 24hrs post-block in hours
Reported as:
Mean · Hours
Time From Block Placement to Onset of Axillary Pain
HoursInterscalene Plus PECS Blocks
Time From Block Placement to Onset of Axillary Pain16.7 (14.1 to 19.3)

Adverse events

Collected over 24 hours. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Interscalene Block Plus Sham Block0/18 (0%)0/18 (0%)0/18 (0%)
Interscalene Plus PECS Blocks0/19 (0%)0/19 (0%)0/19 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Interscalene Block Plus Sham BlockInterscalene Plus PECS BlocksTotal
<=18 years000
Between 18 and 65 years161632
>=65 years235
Sex: Female, Male
Sex: Female, Male(Participants)Interscalene Block Plus Sham BlockInterscalene Plus PECS BlocksTotal
Female5914
Male131023
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Interscalene Block Plus Sham BlockInterscalene Plus PECS BlocksTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American314
White151732
More than one race000
Unknown or Not Reported011
Weight (kg)
Weight (kg)(kg)Interscalene Block Plus Sham BlockInterscalene Plus PECS BlocksTotal
Mean88.1 ± 17.780.7 ± 18.284.3 ± 18.1
BMI
BMI(kg/m^2)Interscalene Block Plus Sham BlockInterscalene Plus PECS BlocksTotal
Mean28.9 ± 4.4426.9 ± 4.5527.8 ± 4.55
Surgical Side (L/R)
Surgical Side (L/R)(Participants)Interscalene Block Plus Sham BlockInterscalene Plus PECS BlocksTotal
Left sided surgery101020
Right sided surgery8917
08

Study locations

1 site
  • Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
09

References and documents

Publications

  • Reynolds JW, Henshaw DS, Jaffe JD, Dobson SW, Edwards CJ, Turner JD, Weller RS, Graves BR, Freehill MT. Analgesic Benefit of Pectoral Nerve Block II Blockade for Open Subpectoral Biceps Tenodesis: A Randomized, Prospective, Double-Blinded, Controlled Trial. Anesth Analg. 2019 Aug;129(2):536-542. doi: 10.1213/ANE.0000000000004233. PubMed 31136331 ↗

Study documents

  • Protocol and statistical analysis plan · Sep 29, 2016

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02741713
Lead sponsor
Wake Forest University Health Sciences
Responsible party
Sponsor
First posted
Apr 18, 2016
Start date
Apr 2016
Primary completion
Jun 29, 2017
Completion
Jun 29, 2017
Results posted
Aug 27, 2018
Last update
Aug 27, 2018

Study contacts

J.Wells Reynolds, MD
principal investigator · Wake Forest Baptist Health Department of Anesthesiology

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion